From 15th to 18th of May, our CEO and CMO will be attending various international events in Hong Kong introducing the latest advances of our company. They will attend Asia Summit on Global Health, Invest in Honk Kong #investHK, and different meeting with local business Angels.
Our CEO Luis Martín Ezama will be attending the #Meet2win23 event 11th and 12th of May, exposing the characteristics of our pipeline of new cancer drugs. We are developing first-in-class antibodies and small molecules against solid tumors.
April 20th. We are going to attend the 19th Annual Anglonordic Life Science Conference.
Meet us to discuss face to face about our latest works: CA04 first-in-class monoclonal antibody, CA05 first-in-class kinase inhibitor and CA07 novel PROTAC.
We can’t wait to hear from you.
CancerAppy closed 2022 with €1.3M total raised.
Cancerappy, together with UCLM, has been awarded the grant from the CCP21 program for the development of nanomedicines (nanoPROTACs), with a total budget of €757,000 and a project duration of 3 years.